At the 2026 American Association for Cancer Research (AACR) Annual Meeting, Ipsen disclosed preclinical research data for the first-in-class (FIC) antibody-drug conjugate (ADC) IPN60300 through two abstracts (Abstract 1665, Abstract 4444) and posters (Poster #1665, Poster #4444), with researchers from Shanghai Escugen Biotechnology Co., Ltd. (Escugen) listed as co-authors. IPN60300 is a novel ADC jointly developed by Escugen and Foreseen Technology (Beijing) Co., Ltd. (Foreseen), which was licensed to Ipsen by Foreseen in July 2024, with a total transaction value of 1.03 billion US dollars. Currently, the candidate is undergoing Phase I/II dose-escalation and expansion clinical trials (NCT07213817).

IPN60300 consists of an ITGA2-targeting antibody conjugated to the innovative linker-payload developed on Escugen’s proprietary EZWiFit™ platform. It is expected to demonstrate superior efficacy over existing standard-of-care therapies across multiple tumor indications, while featuring a favorable safety profile.Preclinical studies confirmed that IPN60300 binds specifically and with high affinity to ITGA2, a target highly expressed in various tumors, enabling efficient internalization of the exatecan payload. Further preclinical data in tumor models demonstrated dose-dependent anti-tumor activity, high tumor-specific accumulation, as well as excellent pharmacokinetic properties and favorable tolerability in non-human primates. The candidate holds the potential to become a first-in-class therapy and improve clinical outcomes.

The preclinical data of IPN60300 validate the safety and efficacy of Escugen’s EZWiFit™ platform. We look forward to the clinical performance of IPN60300, which will further demonstrate the core competitiveness of Escugen’s technology platform, highlight the strong capability of China’s innovative ADC technologies to empower global cancer treatment, and help more patients gain access to better therapeutic options.